AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17612822 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day) plus bupropion (50 mg/day)
Number of subjects: 60
Study 17612822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (n = 178)
Number of subjects: 330
Study 15130379 — intervention group
Group type: COMPARATOR
Intervention: Traditional embryo transfer (n = 152)
Number of subjects: 330
Study 12202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign promoting 30 min of daily walking through paid media, public relations, and public health activities
Number of subjects: 719
Study 12202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign promoting 30 min of daily walking
Number of subjects: 719
Study 12202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeling Walks campaign
Number of subjects: 719
Study 9819794 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 150 U/kg, subcutaneously, three times a week
Number of subjects: 122
Study 9819794 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 300 U/kg, subcutaneously, three times a week
Number of subjects: 122
Study 9819794 — intervention group
Group type: COMPARATOR
Intervention: Control group (open control)
Number of subjects: 122
Study 9819794 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (both dosages)
Number of subjects: 122
Study 8624969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program (ERP) of moderate intensity, frequency, and duration for 3 months, starting approximately 9 weeks post-operatively.
Number of subjects: 49
Study 8624969 — intervention group
Group type: COMPARATOR
Intervention: Standard care without ERP, allowing activity/exercise.
Number of subjects: 49
Study 8624969 — intervention group
Group type: COMPARATOR
Intervention: Both groups reported comparable exercise levels sufficient for training effects to occur.
Number of subjects: 49
Study 29036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments in multi-arm trials
Number of subjects: 0
Study 29036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced and outcome-adaptive randomization methods
Number of subjects: 0
Study 29036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed designs for adding new arms
Number of subjects: 0
Study 29036330 — intervention group
Group type: COMPARATOR
Intervention: Two-arm studies
Number of subjects: 0
Study 29036330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-arm studies
Number of subjects: 0
Study 27271195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1092
Study 27271195 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 1092
Study 27271195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1092
Study 27271195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study 24691757 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h sleep deprivation group
Number of subjects: 24
Study 24691757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 22639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated bone marrow with autologous bone and ceramics
Number of subjects: 15
Study 22639299 — intervention group
Group type: COMPARATOR
Intervention: Unconcentrated bone marrow with autologous bone and ceramics
Number of subjects: 15
Study 19997775 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 21
Study 19997775 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 21
Study 18361007 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% (group B)
Number of subjects: 75
Study 18361007 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus ketamine 0.5 mg/kg (group BK)
Number of subjects: 75
Study 18361007 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus tramadol 1 mg/kg (group BT)
Number of subjects: 75
Study 18361007 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plus ketamine or bupivacaine 0.25% plus tramadol
Number of subjects: 75
Study 16818127 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (8 g)
Number of subjects: 14
Study 16818127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12657919 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole with co-trimoxazole
Number of subjects: 0
Study 12657919 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole without co-trimoxazole
Number of subjects: 0
Study 10758457 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (20 microg kg‐1)
Number of subjects: 100
Study 10758457 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (20 microg kg‐1)
Number of subjects: 100
Study 10758457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 10758457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg kg‐1)
Number of subjects: 100
Study 10758457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg kg‐1)
Number of subjects: 100
Study 10758457 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 8951191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (5 mg kg‐1)
Number of subjects: 8
Study 8951191 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular artemether (5 mg kg‐1)
Number of subjects: 8
Study 8951191 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal artemether (5 mg kg‐1)
Number of subjects: 8
Study 1431008 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 717
Study 1431008 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 717
Study 1431008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 2413563 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied mucopolysaccharide polysulphate
Number of subjects: 10
Study 2413563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29926901 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature intervention of 33°C
Number of subjects: 950
Study 29926901 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature intervention of 36°C
Number of subjects: 950
Study 29926901 — intervention group
Group type: COMPARATOR
Intervention: Temperature intervention of 33°C or 36°C
Number of subjects: 950
Study 26944706 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected perturbation of balance exercises during treadmill walking
Number of subjects: 53
Study 26944706 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking with no perturbations
Number of subjects: 53
Study 25788509 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment in PAC
Number of subjects: 314
Study 25788509 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS2 score of 2
Number of subjects: 314
Study 25788509 — intervention group
Group type: COMPARATOR
Intervention: RE-LY trial
Number of subjects: 314
Study 24172117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response self-monitoring (IVR SM) system with educational modules for 24 weeks
Number of subjects: 70
Study 24172117 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 20060783 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (25 mg aspirin plus 200 mg dipyridamole) twice daily within 24 hours of stroke or TIA onset.
Number of subjects: 543
Study 20060783 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus extended-release dipyridamole (100 mg aspirin) once daily after 7 days of aspirin monotherapy.
Number of subjects: 543
Study 20060783 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (non-fatal stroke, TIA, non-fatal myocardial infarction, major bleeding complications, and mortality).
Number of subjects: 543
Study 17587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg/day) + Bupropion SR (300 mg/day)
Number of subjects: 20
Study 17587504 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR (300 mg/day)
Number of subjects: 20
Study 17587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + Bupropion
Number of subjects: 20
Study 17587504 — intervention group
Group type: COMPARATOR
Intervention: Bupropion only
Number of subjects: 20
Study 16150793 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsules (5 mg kg(‐1))
Number of subjects: 38
Study 16150793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adrenaline infusion (HAdr; adrenaline concentration, 1.2 nM)
Number of subjects: 38
Study 16150793 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adrenaline infusion (LAdr; adrenaline concentration, 0.75 nM)
Number of subjects: 38
Study 16150793 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study 14656350 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers for 12 months
Number of subjects: 0
Study 14656350 — intervention group
Group type: COMPARATOR
Intervention: Placebo bed covers for 12 months
Number of subjects: 0
Study 14656350 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers
Number of subjects: 0
Study 10097224 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 49
Study 10097224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8889901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad (2.5 mg/kg every 3 hours for the first 12 hours, then 2.5 mg/kg every 6 hours for a total of 22 doses over 5 days)
Number of subjects: 20
Study 2068830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 6369854 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 203
Study 6369854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyne T 200
Number of subjects: 203
Study 6369854 — intervention group
Group type: EXPERIMENTAL
Intervention: MLcu 250
Number of subjects: 203
Study 6369854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tcu 200
Number of subjects: 203
Study 30059815 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-oriented psychoeducational programme
Number of subjects: 128
Study 30059815 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 27609859 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (up to 600 mg daily)
Number of subjects: 5215
Study 27609859 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 5215
Study 24760951 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive version of the smoking cessation program
Number of subjects: 23213
Study 24760951 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of 4 modules of the intervention
Number of subjects: 23213
Study 24760951 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking 30 minutes after waking
Number of subjects: 23213
Study 24760951 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking 1 hour after waking
Number of subjects: 23213
Study 22093067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% hexyl nicotinate (HN)
Number of subjects: 10
Study 22093067 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% benzoic acid (BA)
Number of subjects: 10
Study 22093067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625% benzoic acid (BA)
Number of subjects: 10
Study 20832060 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical word segmentation experiments with varying sentence lengths, exposure amounts, and word counts
Number of subjects: 0
Study 20832060 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic models of segmentation
Number of subjects: 0
Study 18266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing humorous films
Number of subjects: 36
Study 18266651 — intervention group
Group type: COMPARATOR
Intervention: Control nonhumorous weather information films
Number of subjects: 36
Study 18266651 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing humorous films after control films
Number of subjects: 36
Study 18266651 — intervention group
Group type: COMPARATOR
Intervention: Control films followed by humorous films
Number of subjects: 36
Study 16630986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin (6 mg loading dose followed by 3 mg/day for 14 days)
Number of subjects: 100
Study 15197517 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide alone (120 mg)
Number of subjects: 18
Study 15197517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide with sulfinpyrazone (400 mg/day for 7 days)
Number of subjects: 18
Study 11074103 — intervention group
Group type: COMPARATOR
Intervention: Lithium (N=15), administered twice daily in doses varying from 1050 to 1950 mg (mean=1569 mg) for 3 weeks.
Number of subjects: 30
Study 11074103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=15), administered for 3 weeks.
Number of subjects: 30
Study 9091474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 3.0 mg/kg per day
Number of subjects: 181
Study 9091474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.5 mg/kg per day
Number of subjects: 181
Study 9091474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 9091474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 5.0 mg/kg per day (induction phase)
Number of subjects: 181
Study 8295188 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 208
Study 8295188 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 208
Study 3305355 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and behavior change group
Number of subjects: 50
Study 3305355 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, behavior change, and exercise group
Number of subjects: 50
Study 3305355 — intervention group
Group type: COMPARATOR
Intervention: Obese control group
Number of subjects: 50
Study 29320553 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed abnormal postpartum blood loss (UPPBL)
Number of subjects: 3917
Study 29320553 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum haemorrhage (PPH)
Number of subjects: 3917
Study 29320553 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPBL
Number of subjects: 3917
Study 29320553 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH
Number of subjects: 3917
Study 29320553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both UPPBL and PPH
Number of subjects: 3917
Study 26886470 — intervention group
Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills (PEERS)
Number of subjects: 0
Study 26886470 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 0
Study 25098487 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led triage
Number of subjects: 20990
Study 25098487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led triage
Number of subjects: 20990
Study 25098487 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20990
Study 22852580 — intervention group
Group type: EXPERIMENTAL
Intervention: BRN-01 tablets (homeopathic medicine containing Actaea racemosa, Arnica montana, Glonoinum, Lachesis mutus, Sanguinaria canadensis)
Number of subjects: 108
Study 22852580 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 108
Study 22852580 — intervention group
Group type: EXPERIMENTAL
Intervention: BRN-01 tablets
Number of subjects: 108
Study 20598970 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN)
Number of subjects: 450
Study 20598970 — intervention group
Group type: COMPARATOR
Intervention: Standard arrhythmia monitoring (control arm)
Number of subjects: 450
Study 18606966 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport) treatment
Number of subjects: 64
Study 18606966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15818323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dac/Tac/MMF
Number of subjects: 538
Study 15818323 — intervention group
Group type: COMPARATOR
Intervention: Tac/MMF/corticosteroids
Number of subjects: 538
Study 12613687 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average backward associative strength (BAS) list items presented by speakers.
Number of subjects: 0
Study 12613687 — intervention group
Group type: COMPARATOR
Intervention: Lower average backward associative strength (BAS) list items presented by speakers.
Number of subjects: 0
Study 10334023 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative mitomycin-C (MMC)
Number of subjects: 25
Study 10334023 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy without MMC
Number of subjects: 25
Study 8877019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene in young subjects (n=18)
Number of subjects: 52
Study 8877019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene in elderly subjects (n=11)
Number of subjects: 52
Study 8877019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene in young subjects (n=8)
Number of subjects: 52
Study 8877019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene in elderly subjects (n=15)
Number of subjects: 52
Study 2020040 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 89
Study 2020040 — intervention group
Group type: COMPARATOR
Intervention: Continuous IV cimetidine
Number of subjects: 89
Study 2020040 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 89
Study 6122890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E
Number of subjects: 126
Study 6122890 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 30365368 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Free Days Questionnaire (SFDQ)
Number of subjects: 1070
Study 27909047 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program
Number of subjects: 296
Study 27909047 — intervention group
Group type: COMPARATOR
Intervention: Normal physical activity (control)
Number of subjects: 296
Study 27652041 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC & RBS herbal medicine
Number of subjects: 360
Study 27652041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 25191937 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI/PGS treatment
Number of subjects: 215
Study 25191937 — intervention group
Group type: COMPARATOR
Intervention: Standard ICSI treatment
Number of subjects: 215
Study 22182496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with atrioventricular optimization (AVO) via SmartDelay or echocardiography
Number of subjects: 846
Study 22182496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular optimization (AVO)
Number of subjects: 846
Study 20517484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 0
Study 20517484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (as monotherapy in early PD and adjunctive therapy in advanced PD)
Number of subjects: 0
Study 20517484 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline
Number of subjects: 0
Study 17645805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention to increase physical activity with a 'Lifestyle script' and telephone counselling for nine months, plus a face-to-face nurse visit at six months
Number of subjects: 0
Study 17645805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 0
Study 16129010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support group (n = 32)
Number of subjects: 96
Study 16129010 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational group (n = 33)
Number of subjects: 96
Study 16129010 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (n = 31)
Number of subjects: 96
Study 12351443 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (hyperinsulinemic-euglycemic clamps at 1, 2, and 4 mU x min(‐1) x kg(‐1)) for 67 hours
Number of subjects: 14
Study 12351443 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 14
Study 10419923 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-ribavirin (3 MU three times weekly + 1-1.2 g ribavirin daily for 6 months)
Number of subjects: 344
Study 10419923 — intervention group
Group type: COMPARATOR
Intervention: IFN monotherapy (3 MU three times weekly for 6 months)
Number of subjects: 344
Study 7593730 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide (450 mg/day) plus thioridazine (100 mg/day)
Number of subjects: 78
Study 7593730 — intervention group
Group type: COMPARATOR
Intervention: moclobemide (450 mg/day) plus placebo
Number of subjects: 78
Study 2147500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 1 g intravenously
Number of subjects: 266
Study 2147500 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 266
Study 6406472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300-600 mg/day)
Number of subjects: 75
Study 6406472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 75
Study 6406472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29912723 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid
Number of subjects: 53
Study 29912723 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 53
Study 29912723 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid and 0.9% saline solution
Number of subjects: 53
Study 30345312 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin-Galactomannoside Complex (CGM) at 250 mg × 2/day for 8 weeks
Number of subjects: 48
Study 30345312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48